Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FOLLISTIM AQ vs CHORIONIC GONADOTROPIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on granulosa cells in the ovary, stimulating follicular growth and maturation via activation of adenylyl cyclase and increased c AMP production.
Chorionic gonadotropin (h CG) binds to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on the surface of gonadal cells, stimulating steroidogenesis and gametogenesis. In females, it triggers ovulation and luteinization; in males, it stimulates Leydig cells to produce testosterone.
Ovulation induction in anovulatory women,Development of multiple follicles in assisted reproductive technologies (ART),Controlled ovarian hyperstimulation for in vitro fertilization (IVF),Hypogonadotropic hypogonadism (off-label)
FDA-approved: Induction of ovulation in infertile females (as part of controlled ovarian hyperstimulation),FDA-approved: Treatment of prepubertal cryptorchidism,FDA-approved: Treatment of hypogonadotropic hypogonadism in males,Off-label: Weight loss (not recommended),Off-label: In vitro fertilization protocols
75 to 300 IU subcutaneously once daily for 8 to 14 days, adjusted based on follicular response; maximum daily dose 450 IU and total duration not exceeding 14 days per cycle.
For hypogonadotropic hypogonadism: 1000-2000 IU subcutaneously or intramuscularly 2-3 times per week. For ovulation induction: 5000-10,000 IU intramuscularly as a single dose.
Terminal elimination half-life approximately 24-36 hours (subcutaneous route); clinical context supports daily dosing due to sustained follicular stimulation.
Biphasic: initial half-life ~11 hours, terminal half-life ~23–30 hours. Single-dose half-life ~32 hours; repeated dosing may extend due to accumulation.
Metabolized via hepatic and renal pathways; exact enzymes not specified.
Primarily metabolized in the liver via proteolytic degradation; undergoes renal excretion with a half-life of 24-36 hours.
Primarily renal (90%), with intact follitropin alfa/beta and metabolites excreted in urine; biliary/fecal excretion minimal (<10%).
Primarily renal; intact h CG is excreted in urine. Negligible biliary/fecal elimination.
Approximately 60-70% bound to plasma proteins, primarily albumin.
Approximately 80% bound; binds to albumin and sex hormone-binding globulin (SHBG) with low affinity.
Approximately 0.5-1.0 L/kg, indicating distribution primarily into extracellular fluid; limited tissue binding.
0.3–0.5 L/kg; distributes into extracellular fluid, gonadal tissues, and poorly into fat.
Subcutaneous injection: approximately 70% (relative to IV); intramuscular injection: approximately 60-70%.
IM/SC: ~40% to 100% (mean ~78%) due to variable absorption; IV: 100% (not typical). Oral: negligible (<1% due to degradation).
No formal guidelines; use with caution in moderate to severe renal impairment (e GFR <30 m L/min/1.73 m²) due to limited data; consider lower starting doses based on clinical response.
No specific dose adjustment guidelines available; use with caution in severe renal impairment (GFR <30 m L/min/1.73 m²).
No formal guidelines; use with caution in Child-Pugh class B or C cirrhosis due to potential altered metabolism; monitor response and consider dose reduction.
No specific dose adjustment guidelines available; use with caution in severe hepatic impairment (Child-Pugh class C).
Not FDA-approved for pediatric use; limited off-label data for anovulatory disorders: start at 75 IU subcutaneously once daily, adjusted per response, based on body weight (1.5-3 IU/kg/day) with careful monitoring.
Cryptorchidism: 500-1000 IU subcutaneously or intramuscularly 2-3 times per week for 6 weeks. Delayed puberty: 500-1500 IU subcutaneously or intramuscularly 2-3 times per week.
Not indicated for geriatric use in fertility; no specific dosing recommendations; consider increased risk of adverse events if used off-label; monitor closely.
No specific dose adjustments; monitor for fluid retention and cardiovascular effects.
None.
None. However, use in females requires careful monitoring to avoid ovarian hyperstimulation syndrome (OHSS), which can be severe.
Ovarian hyperstimulation syndrome (OHSS),Ovarian torsion,Multiple pregnancies,Pulmonary embolism,Ovarian enlargement,Ectopic pregnancy,Congenital malformations
Ovarian hyperstimulation syndrome (OHSS): Risk of severe OHSS with ascites, pleural effusion, and thromboembolic events,Multiple pregnancy: Increased risk due to ovulation induction,Thromboembolic events: Increased risk, especially in patients with prior history,Ovarian enlargement: Monitor with ultrasound,Hormonal-dependent malignancies: Caution in patients with prior history
Hypersensitivity to FSH or excipients,Primary ovarian failure,Ovarian cyst or enlargement of unknown origin,Gynecological cancers (ovarian, breast, uterine),Pregnancy,Uncontrolled thyroid or adrenal dysfunction,Presence of non-gonadal endocrine disorders (e.g., pituitary tumor)
Pregnancy,Primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Active thromboembolic disorder,Hormone-sensitive tumors (e.g., prostate, breast, ovarian),Hypersensitivity to h CG or any component
No significant food interactions. Maintain a healthy diet; no specific restrictions.
No known food interactions.
Follistim Aq (follitropin beta) is classified as Pregnancy Category X. It is contraindicated in pregnant women due to the risk of ovarian hyperstimulation syndrome and potential fetal harm. First trimester: No adequate human data, but animal studies show embryotoxicity. Second and third trimesters: Not indicated for use; may cause fetal harm if inadvertently administered during early pregnancy.
Chorionic gonadotropin is a pregnancy hormone; exogenous use during first trimester may theoretically alter placental hormone balance, but no increased risk of congenital anomalies has been established. However, use during pregnancy is contraindicated except as part of assisted reproductive technology protocols where its role is physiological. No fetal risks documented from therapeutic use in second or third trimester.
Excretion into human milk is unknown. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment. M/P ratio is not available.
Chorionic gonadotropin is not orally bioavailable and is likely degraded in infant gastrointestinal tract. Excretion into breast milk is unknown; M/P ratio not established. However, due to its protein nature, transfer is expected to be minimal. Use during breastfeeding is not recommended unless clearly necessary; theoretical risk of hormonal effects on infant.
Not applicable; Follistim Aq is contraindicated during pregnancy. No pharmacokinetic data are available for pregnant women; thus, no dose adjustments are recommended as the drug should not be used in pregnancy.
No pharmacokinetic dose adjustments are recommended in pregnancy as the drug is typically administered only prior to conception or in early pregnancy for luteal phase support. The endogenous hormone levels in pregnancy far exceed exogenous doses. No dose modification required in later trimesters because use is contraindicated.
Administer subcutaneously; rotate injection sites to avoid lipodystrophy. Do not administer if solution contains particles or discoloration. Use the lowest effective dose to minimize risk of ovarian hyperstimulation syndrome (OHSS). Monitor estradiol levels and ultrasound for follicular development. Discontinue if pregnancy occurs. Store in refrigerator at 2-8°C; do not freeze. Protect from light.
Chorionic gonadotropin (h CG) is used to trigger ovulation in assisted reproduction and to treat hypogonadotropic hypogonadism in males. Monitor for ovarian hyperstimulation syndrome (OHSS) in women; discontinue if severe. Do not use in women with primary ovarian failure. In males, may cause gynecomastia or fluid retention.
Inject exactly as prescribed; do not change dose without consulting your doctor.,Rotate injection sites (abdomen, thigh) to prevent lumps or skin reactions.,Report severe pelvic pain, nausea, vomiting, or rapid weight gain (signs of OHSS) immediately.,Avoid pregnancy during treatment; use barrier contraception until advised by your doctor.,Do not shake the cartridge; gently swirl to mix.,Store in the refrigerator; do not freeze. If unrefrigerated, use within 28 days at room temperature (≤25°C).,Discard any unused solution after the course of treatment.
Report abdominal pain, bloating, nausea, vomiting, or rapid weight gain (signs of OHSS).,In males, report breast tenderness or swelling, or fluid retention (swollen ankles/feet).,Do not use if pregnant or breastfeeding unless directed by a specialist.,For fertility: timing of intercourse or IUI is critical; follow cycle monitoring closely.,In males: take as prescribed for testicular descent or hypogonadism; may require multiple doses.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FOLLISTIM AQ vs CHORIONIC GONADOTROPIN, answered by our medical review team.
FOLLISTIM AQ is a Gonadotropin that works by Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on granulosa cells in the ovary, stimulating follicular growth and maturation via activation of adenylyl cyclase and increased c AMP production.. CHORIONIC GONADOTROPIN is a Gonadotropin Hormone that works by Chorionic gonadotropin (h CG) binds to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on the surface of gonadal cells, stimulating steroidogenesis and gametogenesis. In females, it triggers ovulation and luteinization; in males, it stimulates Leydig cells to produce testosterone.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FOLLISTIM AQ and CHORIONIC GONADOTROPIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FOLLISTIM AQ is: 75 to 300 IU subcutaneously once daily for 8 to 14 days, adjusted based on follicular response; maximum daily dose 450 IU and total duration not exceeding 14 days per cycle.. The standard adult dose of CHORIONIC GONADOTROPIN is: For hypogonadotropic hypogonadism: 1000-2000 IU subcutaneously or intramuscularly 2-3 times per week. For ovulation induction: 5000-10,000 IU intramuscularly as a single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FOLLISTIM AQ and CHORIONIC GONADOTROPIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FOLLISTIM AQ is classified as Category C. Follistim Aq (follitropin beta) is classified as Pregnancy Category X. It is contraindicated in pregnant women due to the risk of ovarian hyperstimulation syndrome and potential fe. CHORIONIC GONADOTROPIN is classified as Category C. Chorionic gonadotropin is a pregnancy hormone; exogenous use during first trimester may theoretically alter placental hormone balance, but no increased risk of congenital anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.